Chronic Kidney Disease-Associated Pruritus
A debilitating condition affecting 50-60% of dialysis patients, characterized by severe generalized itching not originating from skin lesions. Associated with impaired quality of life, sleep disturbance, and depression. Also known as uremic pruritus.
Quick Answer
What it is
A debilitating condition affecting 50-60% of dialysis patients, characterized by severe generalized itching not originating from skin lesions. Associated with impaired quality of life, sleep disturbance, and depression.
Key findings
- Grade A: Itch Intensity Reduction (Difelikefalin (Korsuva))
- Grade A: Itch-Related Quality of Life (Difelikefalin (Korsuva))
- Grade A: Sleep Improvement (Difelikefalin (Korsuva))
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
ℹ️ Quick Facts
Quick Facts: Chronic Kidney Disease-Associated Pruritus
- Supplements Studied:1
1 supps · 3 outcomes
Detailed Outcomes
A
Itch Intensity Reduction
KALM-1/2 Phase 3: 51% achieved ≥3-point WI-NRS reduction vs 28% placebo (P<0.001). Mean 4.2-point decrease vs 2.5-point placebo. Effects sustained up to 64 weeks. First FDA-approved treatment for CKD-aP.
large↓Improves
A
Itch-Related Quality of Life
Pooled analysis: 55.5% achieved ≥15-point Skindex-10 improvement vs 40.5% placebo (P<0.001). 52.1% achieved ≥5-point 5-D Itch improvement vs 42.3% placebo (P=0.01). Sustained benefits to 64 weeks.
large↓Improves
A
Sleep Improvement
Significant improvement in itch-related sleep disturbance. Reduced nighttime awakening due to pruritus. Benefits consistent across demographic and disease characteristic subgroups.
large↑Improves